GHRP-2

GHRP-2 (pralmorelin) is a synthetic peptide and ghrelin receptor agonist that stimulates growth hormone secretion from the pituitary gland for diagnosing growth hormone deficiency.

Brief glance

The primary outcome is Performance, but it's also used for Anti-Aging, Metabolic. This compound is considered a Peptide. It is not currently indicated as compoundable in 503A pharmacies. It is not listed under a DEA schedule.

Overview

GHRP-2, also known as pralmorelin, is a synthetic growth hormone secretagogue that binds to the ghrelin/growth hormone secretagogue receptor to stimulate potent growth hormone release. It promotes lean muscle development by reducing muscle atrophy and boosting protein deposition, while also enhancing appetite and immune function through thymus stimulation. As one of the first GHRPs introduced, it serves as a research tool for assessing growth hormone deficiency and neuroendocrine signaling.

GHRP-2, also known as pralmorelin or KP-102, is a synthetic hexapeptide growth hormone secretagogue that acts as an agonist of the ghrelin receptor (GHS-R1a) to stimulate growth hormone release from the pituitary gland. Developed in the 1980s as a second-generation compound, it inhibits somatostatin while mimicking ghrelin's effects, leading to elevated GH and IGF-1 levels, with a short half-life of 15-60 minutes that favors subcutaneous or intravenous administration. Marketed by Kaken Pharmaceutical in Japan as a diagnostic for growth hormone deficiency, it has been studied for therapeutic potential in short stature, appetite stimulation, tissue repair, and conditions like wasting syndrome. Research also indicates it reliably increases food intake and may support anabolic effects, though oral bioavailability is poor.

Benefits

GHRP-2 stimulates pulsatile growth hormone (GH) secretion from the pituitary gland via binding to ghrelin receptors (GHS-R), elevating GH and IGF-1 levels to promote muscle protein synthesis, reduce muscle atrophy by inactivating degradation pathways like atrogin-1 and MuRF1, and support lean body mass development in catabolic states such as chronic illness.¹,²,³ Clinically, it enhances recovery by accelerating tissue repair, improving connective tissue resilience through increased collagen synthesis, and reducing inflammation, with potential utility in injury rehabilitation and conditions involving muscle wasting.¹,⁴,⁵ Additional effects include improved sleep quality via increased deep sleep stages and REM, thymus stimulation for enhanced T-cell mediated immunity, and possible modulation of pain perception through opioid receptor activity.¹,⁵

Side effects

GHRP-2, a synthetic growth hormone-releasing peptide, commonly causes increased appetite, water retention leading to bloating or joint discomfort, and injection site reactions like redness or pain.⁵,⁶,⁷,⁸ Less common side effects include elevated cortisol and prolactin levels (potentially causing stress, low libido, or gynecomastia), numbness/tingling from fluid pressure on nerves, elevated blood glucose, joint pain, nausea, and mild blood pressure changes.⁵,⁶,⁷,⁸ Key safety considerations involve using it under medical supervision at moderate, cycled doses to minimize dose-dependent risks, monitoring glucose and hormones, and avoiding in those with diabetes, cardiovascular issues, or hormone sensitivities, as studies indicate good tolerability when managed properly but warn of endocrine disruption with misuse.²,⁵,⁷,⁸

Mechanisms of action

GHRP-2 is a synthetic ghrelin mimetic that binds to the growth hormone secretagogue receptor (GHS-R1a), a G-protein-coupled receptor on hypothalamic neurons and pituitary somatotroph cells.⁹,¹⁰ This binding activates intracellular calcium signaling and phospholipase C pathways, triggering pulsatile growth hormone (GH) exocytosis from the anterior pituitary in a cAMP-independent manner.⁹,¹¹,¹² In the hypothalamus, it enhances growth hormone-releasing hormone (GHRH) neuron activity while suppressing somatostatin tone, amplifying GH pulse amplitude.⁹,¹¹ Released GH then stimulates hepatic production of insulin-like growth factor-1 (IGF-1), which activates PI3K/Akt/mTOR pathways to promote protein synthesis and anabolic effects.⁹,¹⁰